Skip to content

Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.

A Study to Evaluate the Results of Integrative Treatment (by Including Ayurvedic Capsules Suved & Reimmugen) for Vascular Disease: Namely: Cerebro Vascular Accident - Embolic and Atherosclerotic, CVA, CAD, IHD,DVT,

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02920125
Acronym
SHARP
Enrollment
96
Registered
2016-09-30
Start date
2016-01-31
Completion date
2017-09-30
Last updated
2017-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebro Vascular Disease, Coronary Artery Disease, Deep Vein Thrombosis, Ischemic Heart Disease, Peripheral Arterial Diseases, Vascular Disease

Keywords

Vascular disease

Brief summary

To evaluate the benefits of Ayurvedic SUVED & REIMMUGEN Colostrum for reduction/reversal of symptoms and study clinical progress in Vascular disease; CAD, CAV, Stroke, DVT patients.

Detailed description

Aim: A non-invasive, effective, compatible, Integrative treatment option to address the growing burden of Vascular disease; Importance: Ayurvedic SUVED (cardio tonic, continuous clotlysis, endothelial repair, powerful rejuvenator, antioxidant) and Reimmugen (Cow Colostrum - IgG, GF) provides sustained Functional, symptomatic relief with clinical reports of regression of disease. No adverse interactions reported. Application: Addition of SUVED & REIMMUGEN helps in: * Acute MI, Thrombotic stroke, DVT, hastens symptomatic recovery, reduces hospitalization time, mortality, helps dissolve clots / soft thrombus; reversal of atherosclerotic plaques; improves functional life * Improvements in Cardiac Function : LVEF; Global perfusion * Rejuvenation of endothelium, vascular function. * Improved physical strength: digestion; GI function; immunity; accelerated internal healing * Secondary prevention to avoid incidences in post event treatment. Health condition/problem studied Vascular disease, esp CVA, IHD, CAD, DVT, PAD Volunteers taken from OPD and IPD of SKNMC & GH with prior consent for participation. Intervention is Medicament based given in addition to conventional ongoing therapy under the guidance of SKNMC doctors. Study type Clinical trial: Double Blind placebo controlled trial. Interventional Trial: regular treatment. Evaluation of additional Integrative esp Ayurvedic medicaments on clinical and functional outcome. Intervention and comparator agent 1. Ayurvedic ghana formulation named SUVED. 2. Whole Cow Colostrum called Reimmugen These will be given for a period of three months in addition to ongoing medication to study the additional benefit to patient in their functional and clinical investigations. The control intervention/s is/are the interventions against which the study intervention is evaluated as double blind placebo. Suved 1 BD for 3 months Reimmugen 1 TDS for 3 months In acute cases Suved 1 TDS Reimmugen 2 TDS for 3 months. Inclusion/ Exclusion criteria Inclusion criteria Adult males or females with a diagnosis of Vascular disease leading to IHD, CAD, CVA, DVT, PAD at any stage. Exclusion Criteria: Pregnant and lactating women, Patients below age of 18 Acute IPD operative condition Patients undergoing interventional procedures / surgical treatments other than for Vascular disease; until they are discharged from intensive care; Haemorrhagic cerebro vascular stroke.

Interventions

DRUGSUVED

Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each

COMBINATION_PRODUCTREIMMUGEN

Whole Cow colostrum in powder put in capsules; 300mg each

OTHERGrain flour placebo

Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos

Sponsors

Smt. Kashibai Navale Medical College and General Hospital
CollaboratorOTHER
Health Solutions, India
CollaboratorINDUSTRY
Sujata Vaidya
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

For subjects/patients -Control and Trial medication are packaged in same looking blister / alu alu strips. For Investigator and Outcome Assessor: no information on patient allocation (trial or Control group)

Intervention model description

Double Blind, Placebo controlled, two arm, on patients of vascular disease / atherosclerosis. Intervention is given in addition to ongoing conventional therapy.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Adult males or females with a diagnosis of Vascular disease leading to IHD, CAD, CVA, DVT, PAD at any stage

Exclusion criteria

* Pregnant and lactating women * Patients below age of 18 * Acute IPD operative condition * Patients undergoing intervention procedures / surgical treatments other than for Vascular disease; until they are discharged from intensive care; Hemorrhagic cerebro vascular stroke

Design outcomes

Primary

MeasureTime frameDescription
changes in IMT as a indicator of atherosclerosis reversal3 months active treatmentRestoration of carotid IMT to non pathological state, supported with positive changes in functionality, relief from associated symptoms during treatment period of 3 months.

Secondary

MeasureTime frameDescription
Assessing the development/risk of ischaemic events in other circulations3 monthsSecondary outcomes assessing the development/risk of ischaemic events in other circulations. Eg; in a stroke patient, evaluation of coronaries. Evaluations done within the study period of 3 months for each patient. To study the occurance of new events in other territory.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026